he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
Fluidigm will develop a microfluidic device for single-cell measurement of epigenetic changes under a broader $27.8 million DARPA-funded project.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.
The research team said its nanofluidic system increased the proportion of nucleic acid and protein disease biomarkers a billionfold prior to detection.
The exact restrictions the injunction will place on 10x are not yet determined. 10x will also have to pay Bio-Rad additional damages, plus interest.
The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.
The University of Michigan researchers aim to commercialize the Hydro-Seq microfluidic platform, which isolates and prepares single circulating tumor cells for RNA sequencing.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.